Undersøgelse af effektivitet og sikkerhed PF-06741086 hos voksne og teenagedeltagere med svær hæmofili A eller moderat svær til svær hæmofili B
En åben-label undersøgelse i unge og voksne alvorlige (koagulationsfaktoraktivitet
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 3
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Pfizer CT.gov Call Center
- Telefonnummer: 1-800-718-1021
- E-mail: ClinicalTrials.gov_Inquiries@pfizer.com
Studiesteder
-
-
-
Sofia, Bulgarien, 1756
- National Specialized Hospital for the Active Treatment of Hematological Diseases - EAD, Sofia
-
Stara Zagora, Bulgarien, 6003
- UMHAT "Prof.Dr. Stoyan Kirkovich"
-
-
-
-
Ontario
-
Hamilton, Ontario, Canada, L8S 4K1
- McMaster University
-
Hamilton, Ontario, Canada, L8S 4K1
- McMaster Children's Hospital
-
Hamilton, Ontario, Canada, L8N 3Z5
- McMaster University Medical Centre - Hamilton Health Sciences
-
Toronto, Ontario, Canada, M5G 1X8
- The Hospital for Sick Children
-
-
-
-
Florida
-
Tampa, Florida, Forenede Stater, 33612
- USF Health Morsani Center for Advanced Healthcare
-
-
Iowa
-
Iowa City, Iowa, Forenede Stater, 52242
- University of Iowa
-
-
New York
-
New Hyde Park, New York, Forenede Stater, 11040
- Northwell Health HTC
-
-
Washington
-
Seattle, Washington, Forenede Stater, 98101
- Washington Institute for Coagulation
-
-
-
-
-
Paris, Frankrig, 75015
- Hôpital Necker Enfants malades
-
-
-
-
-
Hong Kong, Hong Kong
- Queen Mary Hospital
-
Hong Kong, Hong Kong
- Prince of Wales Hospital
-
-
-
-
Gujarat
-
Surat, Gujarat, Indien, 395002
- Nirmal Hospital Pvt, Ltd
-
-
Maharashtra
-
Pune, Maharashtra, Indien, 411004
- Sahyadri Super Speciality Hospital
-
Pune, Maharashtra, Indien, 411004
- Sahyadri Clinical Research And Development Center
-
-
Tamil Nadu
-
Vellore, Tamil Nadu, Indien, 632004
- Christian Medical College
-
-
-
-
-
Perugia, Italien, 06156
- Università degli Studi di Perugia, Azienda Ospedaliera di Perugia, Ospedale Santa Maria della
-
-
Milan
-
Milan, Milan, Italien, 20122
- Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
-
-
RM
-
Roma, RM, Italien, 00161
- Università degli Studi di Roma "Sapienza"-Policlinico Umberto I
-
-
-
-
-
Hiroshima, Japan, 734-8551
- Hiroshima University Hospital
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Japan, 466-8560
- Nagoya University Hospital - Transfusion Medicine
-
-
Hokkaido
-
Sapporo, Hokkaido, Japan, 004-0041
- Sapporo Tokushukai Hospital
-
-
Saitama
-
Iruma-gun, Saitama, Japan, 350-0495
- Saitama Medical University Hospital
-
-
-
-
-
Beijing, Kina, 100045
- Beijing Children's Hospital, Capital Medical University
-
-
Guangdong
-
Guangzhou, Guangdong, Kina, 510515
- Nanfang Hospital, Southern Medical University
-
-
Guizhou
-
Guiyang, Guizhou, Kina, 550004
- The Affiliated Hospital of Guizhou Medical University
-
-
Jiangxi
-
Nanchang, Jiangxi, Kina, 306113
- Jiangxi Provincial People's Hospital
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, Kina, 300020
- Institute of Hematology, Chinese Academy of Medical Sciences
-
-
-
-
-
Zagreb, Kroatien, 10000
- Klinicki bolnicki centar Zagreb
-
-
-
-
Nuevo León
-
Monterrey, Nuevo León, Mexico, 64460
- Hospital Universitario "Dr Jose Eleuterio Gonzalez"
-
-
Yucatán
-
Mérida, Yucatán, Mexico, 97130
- Centro Multidisciplinario para el Desarrollo Especializado de la Inv. Clínica en Yucatán, S.C.P.
-
-
-
-
-
Muscat, Oman, 123
- Sultan Qaboos University Hospital
-
-
-
-
-
Samara, Rusland, 443079
- FGBOU VO "Samara State Medical University" of MoH of Russia
-
-
-
-
-
Jeddah, Saudi Arabien, 21589
- King AbdulAziz University Hospital
-
Riyadh, Saudi Arabien
- King Faisal Specialist Hospital & Research Center
-
-
-
-
-
Belgrade, Serbien, 11000
- Clinical Center of Serbia
-
Belgrade, Serbien, 11000
- Institute for Mother and Child healthcare "Dr Vukan Cupic"
-
Kragujevac, Serbien, 34000
- Clinical Center Kragujevac
-
Niš, Serbien, 18000
- Clinical Center Niš
-
-
-
-
-
A Coruña, Spanien, 15006
- Hospital Universitario A Coruna
-
Barcelona, Spanien, 08035
- Hospital Universitario Vall d´Hebron
-
Madrid, Spanien, 28046
- Hospital Universitario La Paz
-
Salamanca, Spanien, 37007
- Hospital Universitario De Salamanca
-
Zaragoza, Spanien, 50009
- Hospital Universitario Miguel Servet
-
-
-
-
Gauteng
-
Johannesburg, Gauteng, Sydafrika, 2193
- Charlotte Maxeke Johannesburg Academic Hospital
-
-
-
-
-
Daegu, Sydkorea, 41944
- Kyungpook National University Hospital
-
Seoul, Sydkorea, 03722
- Severance Hospital, Yonsei University Health System
-
Seoul, Sydkorea, 05278
- Kyung Hee University Hospital at Gangdong
-
-
-
-
-
Taichung, Taiwan, 40705
- Taichung Veterans General Hospital
-
-
Changhua County
-
Changhua, Changhua County, Taiwan, 500
- Changhua Christian Hospital
-
-
-
-
-
Adana, Tyrkiet (Türkiye), 01130
- Acibadem Adana Hospital
-
Ankara, Tyrkiet (Türkiye), 06230
- Hacettepe University Medical Faculty
-
Ankara, Tyrkiet (Türkiye), 06500
- Gazi University Health Research and Practice Center Gazi Hospital
-
Antalya, Tyrkiet (Türkiye), 07060
- Akdeniz University Medical Faculty
-
Gaziantep, Tyrkiet (Türkiye), 27310
- Gaziantep University Sahinbey Research and Training Hospital
-
Istanbul, Tyrkiet (Türkiye), 34093
- Istanbul University Oncology Institute
-
Izmir, Tyrkiet (Türkiye), 35040
- Ege University Medical Faculty
-
Izmir, Tyrkiet (Türkiye), 35210
- Dr. Behcet Uz Child Diseases Surgery Education and Research Hospital
-
Kayseri, Tyrkiet (Türkiye), 38039
- Erciyes University Medical Faculty
-
Samsun, Tyrkiet (Türkiye), 55280
- Ondokuz Mayıs University Medical Faculty
-
Trabzon, Tyrkiet (Türkiye), 61080
- Karadeniz Technical University Medical Faculty
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Beskrivelse
Inklusionskriterier
- Deltagere med diagnosen svær hæmofili A eller moderat svær til svær hæmofili B med en minimumsvægt på 35 kg ved screening.
- Deltager eller juridisk autoriseret repræsentant eller deltagers omsorgsperson, der er i stand til at give underskrevet informeret samtykke (eller mindre samtykke, hvis det er relevant).
Deltagere, der er tilmeldt Non-Inhibitor Cohort, skal også opfylde følgende kriterier:
- Ingen påviselig eller dokumenteret historie med inhibitorer
- Deltagere på FVIII/FIX rutineprofylakse, som har vist mindst 80 % overensstemmelse med planlagt profylakseregime i løbet af 6 måneder før indskrivning og er villige til at fortsætte med at modtage rutinemæssig profylaksebehandling med FVIII/FIX-erstatning under observationsfasen.
- Deltagere med on-demand behandlingsregime med ≥6 akutte blødningsepisoder (spontane eller traumatiske), der krævede koagulationsfaktorinfusion i løbet af 6 måneders perioden forud for indskrivning og villige til at fortsætte med at modtage on demand-behandling under observationsfasen.
Deltagere, der er tilmeldt inhibitor-kohorten, skal også opfylde følgende kriterier:
- Dokumentation af aktuel højtiterhæmmer (≥5 BU/ml) eller nuværende lavtiterhæmmer (<5 BU/mL), der er refraktær over for FVIII- eller FIX-erstatning og med FVIII- eller FIX-genvinding <60 % af forventet inden for de foregående 6 måneder før indskrivning i observationsfasen
- Hæmofili A-deltagere med on-demand behandlingsregime med ≥6 blødningsepisoder eller hæmofili B-deltagere med ≥4 blødningsepisoder (spontane eller traumatiske), der nødvendiggør behandling med bypass-faktor i løbet af de 6 måneder forud for tilmelding til observationsfasen og villige til at fortsætte med at modtage den -kræve behandling i Observationsfasen.
- Deltagere, der har dokumenteret inhibitorer, mens de var i faktor-erstatningsterapi, men som ikke opfylder de kvantitative inhibitorkriterier beskrevet i det foregående punkt på screeningstidspunktet (f.eks. deltager med en tidligere dokumenteret høj-titer-hæmmer (≥5 BU/ml) og hvis tilstand udelukker genudfordring med FVIII- eller FIX-erstatning) kan overvejes for berettigelse fra sag til sag med forudgående aftale fra Pfizer Medical Monitor
- Deltagere, der opfylder blødningskriterierne nævnt ovenfor, og som er i rutineprofylakse (defineret som behandling ved IV-injektion af bypass-faktor for at forhindre blødning) og har vist mindst 80 % overensstemmelse med planlagt profylakseregime i løbet af de 6 måneder før tilmelding, kan være overvejes for berettigelse fra sag til sag med diskussion og aftale fra Pfizers medicinske monitor.
Eksklusionskriterier
- Tidligere eller nuværende behandling for og/eller historie med koronararteriesygdomme, venøs eller arteriel trombose eller iskæmisk sygdom
- Kendt planlagt kirurgisk indgreb i den planlagte undersøgelsesperiode.
- Kendt hæmostatisk defekt ud over hæmofili A eller B.
- Unormal nyre- eller leverfunktion
- Aktuel ustabil lever- eller galdesygdom
- Unormale hæmatologiske parametre
- Andre akutte eller kroniske medicinske eller psykiatriske tilstande eller laboratorieabnormiteter, der kan øge risikoen forbundet med undersøgelsesdeltagelse eller administration af forsøgsprodukter eller kan interferere med fortolkningen af undersøgelsesresultater og, efter investigatorens vurdering,
- Nuværende rutineprofylakse med bypassagens eller non-koagulation non-faktor-substitutionsterapi eller enhver tidligere behandling med et genterapiprodukt til behandling af hæmofili (deltagere behandlet med profylakse ved hjælp af bypass-midler, eller som tidligere har haft behandling med non-faktor produkter kan være overvejes fra sag til sag).
Regelmæssig, samtidig behandling med immunmodulerende lægemidler
- Løbende eller planlagt brug af immuntolerance-induktion under observationsfasen eller aktiv behandlingsfase, eller profylakse med FVIII eller FIX-erstatning på et hvilket som helst tidspunkt efter påbegyndelse af behandling med undersøgelsesintervention under den aktive behandlingsfase
- Tidligere eksponering for PF 06741086 under deltagelse i undersøgelserne B7841002 og B7841003.
- Deltagelse i andre undersøgelser, der involverer forsøgslægemidler eller forsøgsvacciner inden for 30 dage (eller som bestemt af lokale krav) eller 5 halveringstider før studiestart og/eller under undersøgelsesdeltagelse.
- CD4-celletal ≤200/uL hvis human immundefektvirus (HIV)-positiv
- Screening af EKG, der viser klinisk relevante abnormiteter, der kan påvirke deltagernes sikkerhed eller fortolkning af undersøgelsesresultater.
- Personer med overfølsomhed eller en allergisk reaktion over for hamsterprotein eller andre komponenter i undersøgelsesinterventionen.
- Medlemmer af efterforskerstedet, der er direkte involveret i udførelsen af undersøgelsen og deres familiemedlemmer, medlemmer af stedets personale, der på anden måde er overvåget af investigatoren, eller deltagere, som er Pfizer-ansatte, inklusive deres familiemedlemmer, direkte involveret i udførelsen af undersøgelsen.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Crossover opgave
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: PF-06741086
Deltagerne vil blive tildelt behandling med PF-06741086 efter en 6 måneders observationsfase på deres nuværende hæmofili-regime.
|
300 milligram(mg) subkutan (sc) ladningsdosis efterfulgt af 150 mg sq én gang om ugen (qw).
300 mg sc qw er ordineret til deltagere, der opfylder dosiseskaleringskriterier.
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Model-Based Annualized Bleeding Rate (ABR) of Treated Bleeding Events: Inhibitor Cohort (Participants With Prior OD Therapy at OP)
Tidsramme: OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
ABR is defined as number of bleeding episodes per year.
ABR was calculated as number of bleeds requiring treatments/ (days on treatment period/365.25).
If a participant did not complete a treatment period, days on treatment ended at last dosing date + 6 days.
Treated bleed: If a bleed was treated with factor replacement or bypass agents within 48 hours of start of bleeding, regardless of the type of treatment (preventive, prophylaxis or OD medication).
A model-based ABR using a repeated measures negative binomial model is reported for this outcome measure.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
|
Model-Based ABR of Treated Bleeding Events: Non-Inhibitor Cohort (Participants With Prior OD Therapy at OP)
Tidsramme: OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
ABR is defined as number of bleeding episodes per year.
ABR was calculated as number of bleeds requiring treatments/ (days on treatment period/365.25).
If a participant did not complete a treatment period, days on treatment ended at last dosing date + 6 days.
Treated bleed: If a bleed was treated with factor replacement or bypass agents within 48 hours of start of bleeding, regardless of the type of treatment (preventive, prophylaxis or OD medication).
A model-based ABR using a repeated measures negative binomial model is reported for this outcome measure.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
|
Model-Based ABR of Treated Bleeding Events: Non-Inhibitor Cohort (Participants With RP at OP)
Tidsramme: OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
ABR is defined as number of bleeding episodes per year.
ABR was calculated as number of bleeds requiring treatments/ (days on treatment period/365.25).
If a participant did not complete a treatment period, days on treatment ended at last dosing date + 6 days.
Treated bleed: If a bleed was treated with factor replacement or bypass agents within 48 hours of start of bleeding, regardless of the type of treatment (preventive, prophylaxis or OD medication).
A model-based ABR using a repeated measures negative binomial model is reported for this outcome measure.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
|
Number of Participants With Adverse Events (AEs): Inhibitor and Non-Inhibitor Cohort
Tidsramme: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
AEs included both serious AEs and all other AEs.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
|
Number of Participants With Serious Adverse Events (SAEs): Inhibitor and Non-Inhibitor Cohort
Tidsramme: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
AE: any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
SAE: any untoward medical occurrence at any dose that resulted in any of the following outcomes: death; life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; or that was considered as an important medical event.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
|
Number of Participants With Thrombotic Events: Inhibitor and Non-Inhibitor Cohort
Tidsramme: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
Thrombotic events are when a blood clot (thrombus) forms in a blood vessel in the arm, leg, lung, or head and can be life-threatening.
A thrombus can occur in veins (venous thrombosis) or arteries (arterial thrombosis).
|
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
|
Number of Participants With Thrombotic Microangiopathy: Inhibitor and Non-Inhibitor Cohort
Tidsramme: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
Thrombotic microangiopathy: pathological state where micro-vessels are occluded by platelet rich thrombi leading to thrombocytopenia (low platelets) and microangiopathic haemolytic anaemia (red blood cell destruction) and potential end organ damage.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
|
Number of Participants With Disseminated Intravascular Coagulation/ Consumption Coagulopathy: Inhibitor and Non-Inhibitor Cohort
Tidsramme: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
Disseminated intravascular coagulation is characterized by widespread clotting in small blood vessels, and consumption of platelets and clotting factors by the clots, leading to bleeding.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
|
Number of Participants With Anti-drug Antibodies (ADA) and Neutralizing Antibodies (NAb) Against PF- 06741086: Inhibitor and Non-Inhibitor Cohort
Tidsramme: During prophylaxis treatment in ATP (12 months)
|
ADA positive: A participant with >=1 treatment induced or treatment-boosted ADA response.
NAb positive: An ADA positive participant with >=1 treatment induced or treatment boosted NAb response.
|
During prophylaxis treatment in ATP (12 months)
|
|
Number of Participants With Transient and Persistent ADA and NAb Against PF-06741086: Inhibitor and Non-Inhibitor Cohort
Tidsramme: During prophylaxis treatment in ATP (12 months)
|
Persistent ADA: participant with treatment-induced or treatment-boosted ADA detected at 2 or more times during treatment including any follow-up, where first and last ADA positive samples separated by >=16 weeks.
Transient ADA: treatment-induced or treatment-boosted ADA detected at only 1 time during treatment or follow-up.
Persistent NAb: NAb-positive participant with first and last positive NAb samples detected >=16 weeks posttreatment, irrespective of any negative samples in between.
Transient NAb: NAb-positive participant with (1) treatment-induced/treatment-boosted NAb sample detected at only 1 time posttreatment or (2) treatment-induced/treatment-boosted NAb samples detected at 2 or more times where first and last positive samples separated by <16 weeks, and participant's last sample was NAb or ADA negative.
|
During prophylaxis treatment in ATP (12 months)
|
|
Number of Participants With Injection Site Reactions (ISRs): Inhibitor and Non-Inhibitor Cohort
Tidsramme: During prophylaxis treatment in ATP (12 months)
|
ISR included: injection site haematoma, injection site pain, injection site bruising, injection site erythema, injection site induration, injection site oedema, Injection site pruritus and Injection site swelling.
ISR graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 where grade 1: tenderness with or without associated symptoms (warmth, erythema, itching), grade 2: pain, lipodystrophy, edema, phlebitis, grade 3: ulceration or necrosis, severe tissue damage, operative intervention indicated, grade 4: life-threatening consequences, urgent intervention indicated and grade 5: death.
In this outcome measure only categories with non-zero values reported.
|
During prophylaxis treatment in ATP (12 months)
|
|
Number of Participants With Clinically Significant Changes in Physical Examinations: Inhibitor and Non-Inhibitor Cohort
Tidsramme: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
Physical examination included assessments of the head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems.
Height and weight were also measured and recorded.
Clinical significance in physical examinations was determined by investigator.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
|
Number of Participants With Clinically Significant Changes in Vital Signs: Inhibitor and Non-Inhibitor Cohort
Tidsramme: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
Vital signs included temperature, pulse rate, respiratory rate, and blood pressure.
Blood pressure and pulse rate were measured in a supine position using completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions.
Respiratory rate was measured by observing and counting the respirations of the participant for 30 seconds and multiplied by 2. Clinical significance of vital signs was determined by investigator.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
|
Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters: Inhibitor and Non-Inhibitor Cohort
Tidsramme: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
Hematology included: hemoglobin; leukocytes; neutrophils; and platelets.
Chemistry included: potassium; aspartate aminotransferase; creatinine; alkaline phosphatase; total bilirubin; albumin; calcium corrected, estimated decreased; sodium; and calcium.
Clinical significance of laboratory parameters was determined by investigator.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
|
Number of Participants With Severe/ Systematic Hypersensitivity and Anaphylactic Reactions: Inhibitor and Non-Inhibitor Cohort
Tidsramme: During prophylaxis treatment in ATP (12 months)
|
Systemic hypersensitivity is a complex immune response where the immune system reacts excessively to an antigen, often leading to severe allergic reactions, including widespread symptoms (which may affect multiple organs), such as rash, swelling of your face, lips, mouth, or tongue, trouble breathing, wheezing, dizziness, fainting, fast heartbeat, pounding in your chest or sweating.
Anaphylaxis is a severe, potentially fatal, systemic allergic reaction that occurs suddenly after contact with an allergy causing substance.
|
During prophylaxis treatment in ATP (12 months)
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Model-Based ABR of Joint Bleeds: Inhibitor and Non-Inhibitor Cohort
Tidsramme: OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
ABR: number of bleeding episodes per year.
ABR was calculated as number of bleeds requiring treatments/ (days on treatment period/365.25).
If a participant did not complete a treatment period, days on treatment ended at last dosing date + 6 days.
Joint bleed: bleeding episode characterized by rapid loss of range of motion as compared with baseline that was associated with any combination of the following: pain or an unusual sensation in the joint, palpable swelling, and warmth of the skin over the joint.
A model-based ABR using a repeated measures negative binomial model is reported for this outcome measure.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
|
Model-Based ABR of Spontaneous Bleeds: Inhibitor and Non-Inhibitor Cohort
Tidsramme: OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
ABR: number of bleeding episodes per year.
ABR was calculated as the number of bleeds requiring treatments/ (days on treatment period/365.25).
If a participant did not complete a treatment period, the days on treatment ended at the last dosing date + 6 days.
Spontaneous bleed: Bleeding for no apparent/known reason particularly into the joints, muscles, and soft tissues.
A model-based ABR using a repeated measures negative binomial model is reported for this outcome measure.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
|
Model-Based ABR of Target Joint Bleeds: Inhibitor and Non-Inhibitor Cohort
Tidsramme: OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
ABR: number of bleeding episodes per year.
ABR was calculated as number of bleeds requiring treatments/ (days on treatment period/365.25).
If participant did not complete a treatment period, days on treatment ended at last dosing date + 6 days.
Target joint: a major joint into which repeated bleeds occurred.
Joint bleed: bleeding episode characterized by rapid loss of range of motion as compared with baseline that was associated with any combination of following: pain or unusual sensation in joint, palpable swelling, and warmth of the skin over joint.
A model-based ABR using a repeated measures negative binomial model is reported for this outcome measure.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
|
Model-Based ABR of Total Bleeds: Inhibitor and Non-Inhibitor Cohort
Tidsramme: OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
ABR: number of bleeding episodes per year.
ABR was calculated as number of bleeds requiring treatments/ (days on treatment period/365.25).
If participant did not complete treatment period, days on treatment ended at last dosing date + 6 days.
Treated bleed: If a bleed was treated with factor replacement or bypass agents within 48 hours of start of bleeding, regardless of the type of treatment (preventive, prophylaxis or on-demand medication).
Untreated bleed: If a bleed was untreated with factor replacement or bypass agents within 48 hours of start of bleeding, regardless of the type of treatment (preventive, prophylaxis or on-demand medication), it was considered as an untreated bleed.
Total bleeds: Treated bleeds + untreated bleeds.
A model-based ABR using a repeated measures negative binomial model is reported for this outcome measure.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
|
Change From Baseline in Hemophilia Joint Health Score (HJHS) at Month 6: Non-Inhibitor Cohort
Tidsramme: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
HJHS evaluated total joint score for 6 joints (left ankle, right ankle, left elbow, right elbow, left knee, right knee) and the global gait score.
Joint total score per joint ranged from 0 to 20 (evaluated as: swelling [0-3], duration of swelling [0-1], muscle atrophy [0-2], crepitus on motion [0-2], flexion loss [0-3], extension loss [0-3], joint pain [0-2], and strength [0-4]).
Global gait score ranged from 0 to 4 based on walking, stairs, running, and hopping on 1 leg.
HJHS total score was sum of total joint score for 6 joints (0 to 120) and global gait score (0 to 4).
The total HJHS score ranged from 0 to 124, where higher scores indicated worse joint health.
|
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
|
Change From Baseline in HJHS at Month 6: Inhibitor Cohort
Tidsramme: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
HJHS evaluated total joint score for 6 joints (left ankle, right ankle, left elbow, right elbow, left knee, right knee) and the global gait score.
Joint total score per joint ranged from 0 to 20 (evaluated as: swelling [0-3], duration of swelling [0-1], muscle atrophy [0-2], crepitus on motion [0-2], flexion loss [0-3], extension loss [0-3], joint pain [0-2], and strength [0-4]).
Global gait score ranged from 0 to 4 based on walking, stairs, running, and hopping on 1 leg.
HJHS total score was sum of total joint score for 6 joints (0 to 120) and global gait score (0 to 4).
The total HJHS score ranged from 0 to 124, where higher scores indicated worse joint health.
|
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
|
Change From Baseline in Hemophilia Quality of Life Questionnaire for Adults (Haem-A-QoL) Total Score and Physical Health Domain at Month 6: Non-Inhibitor Cohort, Participants >=17 Years
Tidsramme: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
Haem-A-QoL assessed health-related quality of life (QoL) in adult participants (>=17 years of age) with hemophilia.
It contained 46 items with 10 domains that assessed health in the following areas: physical health; feelings; view of self; sports and leisure; work and school; dealing with haemophilia; treatment; future; family planning; partnership and sexuality.
All items were based on a 5-point Likert type scale (1= never, 2= rarely, 3= sometimes, 4= often, 5= all the time).
Scoring was performed by averaging non-missing item responses for each domain, then each domain score was rescaled from 0 to 100, lower scores signified higher QoL.
Total Haem-A-QoL score was averaged across the 46 items values and then rescaled from 0 to 100, lower Haem-A-QoL scores signified better QoL.
|
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
|
Change From Baseline in Haem-A-QoL Total Score and Physical Health Domain at Month 6: Inhibitor Cohort, Participants >=17 Years
Tidsramme: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
Haem-A-QoL assessed health-related quality of life (QoL) in adult participants (>=17 years of age) with hemophilia.
It contained 46 items with 10 domains that assessed health in the following areas: physical health; feelings; view of self; sports and leisure; work and school; dealing with haemophilia; treatment; future; family planning; partnership and sexuality.
All items were based on a 5-point Likert type scale (1= never, 2= rarely, 3= sometimes, 4= often, 5= all the time).
Scoring was performed by averaging non-missing item responses for each domain, then each domain score was rescaled from 0 to 100, lower scores signified higher QoL.
Total Haem-A-QoL score was averaged across the 46 items values and then rescaled from 0 to 100, lower Haem-A-QoL scores signified better QoL.
|
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
|
Change From Baseline in Hemophilia Quality of Life Questionnaire for Children (Haemo-QoL) Total Score at Month 6: Non-Inhibitor Cohort, Participants 12 to <17 Years
Tidsramme: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
Haemo-QoL assessed health-related QoL in adolescent participants (12 to <17 years of age) with hemophilia.
It contains 12 items with 77 domains that assesses health in the following areas: physical health; feelings; attitude/view; family; friends; other people; sport and school; coping/dealing; treatment; perceived support; future and relationship.
All items were based on 5-point Likert type scale (1= never, 2= rarely, 3= sometimes, 4= often, 5= all the time).
Scoring was performed by averaging non-missing item responses for each domain, then rescaled from 0 to 100, lower scores signified higher QoL.
Total Haem-A QoL score was averaged across the 77 items values and then rescaled from 0 to 100, lower Haemo-QoL scores signified better QoL.
|
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
|
Change From Baseline in Haemo-QoL Total Score at Month 6: Inhibitor Cohort, Participants 12 to <17 Years
Tidsramme: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
Haemo-QoL assessed health-related QoL in adolescent participants (12 to <17 years of age) with hemophilia.
It contains 12 items with 77 domains that assesses health in the following areas: physical health; feelings; attitude/view; family; friends; other people; sport and school; coping/dealing; treatment; perceived support; future and relationship.
All items were based on 5-point Likert type scale (1= never, 2= rarely, 3= sometimes, 4= often, 5= all the time).
Scoring was performed by averaging non-missing item responses for each domain, then rescaled from 0 to 100, lower scores signified higher QoL.
Total Haem-A QoL score was averaged across the 77 items values and then rescaled from 0 to 100, lower Haemo-QoL scores signified better QoL.
|
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
|
Change From Baseline in Hemophilia Activities List (HAL) Total Score at Month 6: Non-Inhibitor Cohort, Participants >=17 Years
Tidsramme: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
The HAL was a multiple domain measure of the impact of hemophilia on functional abilities in adults (>=17 years of age).
The 7 domains of this instrument contained 42 items in total, as follows: lying/sitting/kneeling/standing; lower (leg) functioning; upper (arm) functioning; transportation; self-care; household tasks; and sports/leisure.
Items were rated on 6-point scale 1 (impossible) to 6 (never) that described difficulty due to hemophilia.
HAL total score was sum of all items and scored 42 to 252, which were transformed to 0 - 100, where higher scores indicated better functional status.
|
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
|
Change From Baseline in HAL Total Score at Month 6: Inhibitor Cohort, Participants >=17 Years
Tidsramme: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
The HAL was a multiple domain measure of the impact of hemophilia on functional abilities in adults (>=17 years of age).
The 7 domains of this instrument contained 42 items in total, as follows: lying/sitting/kneeling/standing; lower (leg) functioning; upper (arm) functioning; transportation; self-care; household tasks; and sports/leisure.
Items were rated on 6-point scale 1 (impossible) to 6 (never) that described difficulty due to hemophilia.
HAL total score was sum of all items and scored 42 to 252, which were transformed to 0 - 100, where higher scores indicated better functional status.
|
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
|
Change From Baseline in Pediatric Hemophilia Activities List (pedHAL) Total Score at Month 6: Non-Inhibitor Cohort, Participants 12 to <17 Years
Tidsramme: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
The pedHAL was a multiple domain measure of the impact of hemophilia on functional abilities in adolescents (12 to <17 years of age).
The 7 domains of this instrument contained 53 items in total, as follows: sitting/kneeling/standing; functions of the legs; functions of the arms; use of transportation; self-care; household tasks; leisure activities and sports.
Items were rated on 6-point scale 1 (impossible) to 6 (never) that described difficulty due to hemophilia.
pedHAL total score was normalized in a range of 0 - 100, where higher scores indicated better functional status.
|
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
|
Change From Baseline in pedHAL Total Score at Month 6: Inhibitor Cohort, Participants 12 to <17 Years
Tidsramme: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
The pedHAL was a multiple domain measure of the impact of hemophilia on functional abilities in adolescents (12 to <17 years of age).
The 7 domains of this instrument contained 53 items in total, as follows: sitting/kneeling/standing; functions of the legs; functions of the arms; use of transportation; self-care; household tasks; leisure activities and sports.
Items were rated on 6-point scale 1 (impossible) to 6 (never) that described difficulty due to hemophilia.
pedHAL total score was normalized in a range of 0 - 100, where higher scores indicated better functional status.
|
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
|
Patient Global Impression of Change-Hemophilia (PGIC-H) at Month 6: Non-Inhibitor Cohort
Tidsramme: Month 6
|
The PGIC-H was a single item assessment of the participant's overall impression of change in their life with hemophilia, on a 7-point scale (1= greatly improved to 7= greatly worsened, where lower scores indicated better improvement).
|
Month 6
|
|
PGIC-H at Month 6: Inhibitor Cohort
Tidsramme: Month 6
|
The PGIC-H was a single item assessment of the participant's overall impression of change in their life with hemophilia, on a 7-point scale (1= greatly improved to 7= greatly worsened, where lower scores indicated better improvement).
|
Month 6
|
|
Change From Baseline in EuroQol 5 Dimensions 5 Level (EQ-5D-5L) Index and VAS Scores at Month 6: Non-Inhibitor Cohort
Tidsramme: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
EQ-5D-5L consisted of participant completed questionnaire with 2 components: health state profile index and visual analogue scale (VAS).
EQ-5D health state profile index has 5 domains (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), with 5 levels (1= no problems, 2= slight problems, 3= moderate problems, 4= severe problems, 5= extreme problems).
Responses to 5 dimensions comprised health state index value.
E.g. if a participant responds "no problems" for each 5 dimensions, then health state was coded as "11111" with predefined index value to it.
EQ-5D-5L index score ranged from -0.594 to 1, United Kingdom look-up value was applied to all participants, higher scores indicated better health states.
The EQ- VAS measured participant's self-rated health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state) by VAS, where higher scores indicated better heath states.
|
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
|
Change From Baseline in EQ-5D-5L Index and VAS Scores at Month 6: Inhibitor Cohort
Tidsramme: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
EQ-5D-5L consisted of participant completed questionnaire with 2 components: health state profile index and visual analogue scale (VAS).
EQ-5D health state profile index has 5 domains (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), with 5 levels (1= no problems, 2= slight problems, 3= moderate problems, 4= severe problems, 5= extreme problems).
Responses to 5 dimensions comprised health state index value.
E.g. if a participant responds "no problems" for each 5 dimensions, then health state was coded as "11111" with predefined index value to it.
EQ-5D-5L index score ranged from -0.594 to 1, United Kingdom look-up value was applied to all participants, higher scores indicated better health states.
The EQ- VAS measured participant's self-rated health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state) by VAS, where higher scores indicated better heath states.
|
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studieleder: Pfizer CT.gov Call Center, Pfizer
Publikationer og nyttige links
Generelle publikationer
- Matino D, Acharya SS, Taylor CT, Sun P, Agathon D, Raje S, Gould T, Palladino A, Mahlangu J, Lissitchkov T, Todorova M, Chan A, Carcao M, Sun J, Yang R, Wu R, Jin C, Zeng X, Boban A, Bilic E, Frenzel L, Fung Chan GC, Kong Li C, Apte S, Choraria N, Chistolini A, Marchesini E, Peyvandi F, Fujii T, Matsushita T, Kaneda M, Lyu CJ, Park YS, Kim S, Martinez LV, Adrian JM, Wali Y, Al Khabori M, Kurtov I, Alzahrani H, Zaher G, Micic D, Miljic P, Kostic G, Vucic M, Djurdjevic P, Hidalgo OB, Porras JG, Jimenez-Yuste V, Calvo Villas JM, Lopez Fernandez MF, Albayrak C, Okan V, Balkan C, Sahin F, Antmen A, Unal E, Visweshwar N, Sharathkumar A, Kruse-Jarres R. Efficacy and safety of marstacimab prophylaxis in hemophilia A/B with inhibitors: results from the phase 3 BASIS trial. Blood. 2026 Feb 26;147(9):920-931. doi: 10.1182/blood.2025031065.
- Matino D, Palladino A, Taylor CT, Hwang E, Raje S, Nayak S, McDonald R, Acharya SS, Mahlangu J, Jimenez-Yuste V, Choraria N, Yang R, Li CK, Al-Khabori M, Wali Y, Morales Adrian J, Park YS, Zulfikar OB, Teeter J. Marstacimab prophylaxis in hemophilia A/B without inhibitors: results from the phase 3 BASIS trial. Blood. 2025 Oct 2;146(14):1654-1663. doi: 10.1182/blood.2024027468.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Patologiske processer
- Genetiske sygdomme, medfødte
- Hæmatologiske sygdomme
- Blodkoagulationsforstyrrelser
- Hæmoragiske lidelser
- Genetiske sygdomme, X-forbundet
- Blodkoagulationsforstyrrelser, arvelig
- Koagulationsproteinforstyrrelser
- Medfødte, arvelige og neonatale sygdomme og abnormiteter
- Patologiske tilstande, tegn og symptomer
- Hemiske og lymfatiske sygdomme
- Hæmofili A
- Blødning
- Hæmofili B
- Marstacimab
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- B7841005
- 2018-003660-31 (EudraCT nummer)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .